| Pharmaceutical Information |
| Drug Name |
Teriparatide |
| Drug ID |
BADD_D02166 |
| Description |
Teriparatide (recombinant human parathyroid hormone) is a potent anabolic agent used in the treatment of osteoporosis. It is manufactured and marketed by Eli Lilly and Company. |
| Indications and Usage |
For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. |
| Marketing Status |
Discontinued; Prescription |
| ATC Code |
H05AA02 |
| DrugBank ID |
DB06285
|
| KEGG ID |
D06078
|
| MeSH ID |
D019379
|
| PubChem ID |
16133850
|
| TTD Drug ID |
D0YA2L
|
| NDC Product Code |
63557-0021; 69766-088; 32861-0008; 68594-030; 47781-652; 0002-8400; 52221-119; 41524-0010; 65129-1312 |
| Synonyms |
Teriparatide | hPTH (1-34) | Human Parathyroid Hormone (1-34) | Parathar | Teriparatide Acetate | Forteo |
|
| Chemical Information |
| Molecular Formula |
C181H291N55O51S2 |
| CAS Registry Number |
52232-67-4 |
| SMILES |
CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(
CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(
=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)N
C(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC
(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)
O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)N
C(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
